Albamed s.r.o.
- Address
- lock Available on a paid plan
Immune System Diseases
At Albamed s.r.o. in Zvolen, clinical research in rheumatology focuses on immune system diseases such as Primary Sjögren’s Disease, Sjögren’s Syndrome, Rheumatoid Arthritis, and Systemic Lupus Erythematosus. The trials are designed to test new treatments and better understand how to reduce disease activity and improve patient outcomes.
- Evaluating novel therapies for Sjögren’s Syndrome and related autoimmune conditions
- Measuring changes in systemic disease activity and symptom control in Primary Sjögren’s Disease
- Assessing treatment effectiveness for Systemic Lupus Erythematosus in patients with moderate to severe disease
These studies aim to determine whether investigational approaches can outperform placebo and support better long-term management for people living with chronic autoimmune illness.
Skin and Connective Tissue Diseases
Research at this hospital/clinic also includes skin and connective tissue diseases, with a strong focus on Psoriatic arthritis. The work is centered on evaluating new therapies that may ease joint inflammation, improve physical function, and provide more effective options for people with active disease.
- Testing a new treatment approach for Psoriatic arthritis
- Studying improvements in joint symptoms and overall disease control
- Comparing active therapy with placebo to understand treatment benefit
Across this area, the site contributes to research aimed at improving care for inflammatory conditions that affect both the skin and joints.
Autoimmune Treatment Safety and Effectiveness
The clinical trial portfolio at Albamed s.r.o. includes studies that compare established and emerging therapies in rheumatoid arthritis and related autoimmune diseases. A key research goal is to evaluate treatment effectiveness while also examining safety and tolerability in everyday clinical use.
- Comparing therapies for Rheumatoid Arthritis to understand relative benefit
- Assessing safety outcomes alongside symptom improvement
- Supporting better treatment choices for chronic inflammatory disease
These investigations help clarify how new and existing medicines may fit into routine care for patients with long-term rheumatic conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Albamed s.r.o.
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period | AbbVie Deutschland GmbH & Co. KG | Phase III | Not Recruiting | Mar 2020 | Apr 2024 |
IMP list
lock Showing 1 of 13 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ianalumab | 3 | Unknown | 2022-08-04 | 2023-10-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.